TH5427（Cat No.:I043731）is a potent, selective inhibitor targeting the enzyme CDK7 (Cyclin-Dependent Kinase 7), a key regulator in the cell cycle and transcriptional regulation. By inhibiting CDK7, TH5427 disrupts the transcriptional machinery and cell cycle progression, leading to cancer cell death. This compound is particularly effective against cancers with high levels of CDK7 activity, such as certain types of leukemia and solid tumors. TH5427 shows potential as a therapeutic agent in oncology, offering a novel approach to target tumor growth and proliferation by disrupting key regulatory pathways.